Canaccord Genuity reaffirmed their buy rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research note issued to investors on Saturday morning. They currently have a $10.00 price objective on the stock.

Several other research firms have also recently commented on AUPH. HC Wainwright started coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a buy rating and a $7.00 price target on the stock. FBR & Co restated an outperform rating and set a $9.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. Finally, Leerink Swann restated an outperform rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $7.75.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The stock’s 50 day moving average price is $2.45 and its 200-day moving average price is $2.78. Aurinia Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $5.69. The stock’s market capitalization is $165.84 million.

A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Abingworth LLP raised its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 479.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 512,036 shares of the company’s stock after buying an additional 423,729 shares during the period. Aurinia Pharmaceuticals makes up approximately 1.5% of Abingworth LLP’s holdings, making the stock its 16th largest position. Abingworth LLP owned 1.56% of Aurinia Pharmaceuticals worth $1,388,000 at the end of the most recent quarter. 20.04% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.